Skip to main
MAZE

MAZE Stock Forecast & Price Target

MAZE Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Maze Therapeutics Inc. is leveraging its innovative Compass platform to identify and target genetic variants for the development of novel precision medicines, specifically addressing chronic kidney disease with its promising programs, MZE829 and MZE782. Preliminary Phase 1 data indicate significant efficacy signals, with MZE782 demonstrating a 39-fold increase in urinary phenylalanine and supportive pharmacokinetic profiles, suggesting a competitive advantage over existing treatments in the market. Furthermore, the anticipated regulatory momentum for MZE829, bolstered by improved diagnosis and treatment protocols, enhances the likelihood of accelerated approval, positioning Maze Therapeutics favorably within the biopharmaceutical landscape.

Bears say

The analysis of Maze Therapeutics, Inc. indicates a cautious outlook primarily due to the risks associated with its investigational drug inaxaplin, which may lead to an inflated perception of its efficacy. Additionally, the complexities surrounding chronic kidney disease (CKD), particularly in patients experiencing variable responses to SGLT2 inhibitors and the potential for significant eGFR declines, contribute to substantial uncertainties in trial outcomes. Furthermore, indications that a significant portion of patients may not respond adequately to existing therapies amplify concerns regarding the commercial viability and success of the company’s precision medicine initiatives.

MAZE has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Maze Therapeutics Inc (MAZE) Forecast

Analysts have given MAZE a Buy based on their latest research and market trends.

According to 7 analysts, MAZE has a Buy consensus rating as of Jan 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Maze Therapeutics Inc (MAZE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.